Inclacumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetselectin P
Clinical data
Other namesLC1004-002
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6452H9930N1730O2024S42
Molar mass145465.02 g·mol−1

Inclacumab (LC1004-002) (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease.[1][2][3][4][5][6][7][8][9]

The antibody is outlicensed by Roche.[10]

References

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Inclacumab, American Medical Association.
  3. ^ Stähli BE, Gebhard C, Duchatelle V, Cournoyer D, Petroni T, Tanguay JF, Robb S, Mann J, Guertin MC, Wright RS, L L'Allier P, Tardif JC (November 2016). "Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial". J Am Heart Assoc. 5 (11). doi:10.1161/JAHA.116.004255. PMC 5210344. PMID 27852589.
  4. ^ Stähli BE, Tardif JC, Carrier M, Gallo R, Emery RW, Robb S, Cournoyer D, Blondeau L, Johnson D, Mann J, Lespérance J, Guertin MC, L'Allier PL (January 2016). "Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial". J. Am. Coll. Cardiol. 67 (3): 344–6. doi:10.1016/j.jacc.2015.10.071. PMID 26796402.
  5. ^ Morrison M, Palermo G, Schmitt C (November 2015). "Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects". Eur. J. Clin. Pharmacol. 71 (11): 1365–74. doi:10.1007/s00228-015-1938-4. PMID 26363899. S2CID 468125.
  6. ^ Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J (June 2015). "First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin". J. Cardiovasc. Pharmacol. 65 (6): 611–9. doi:10.1097/FJC.0000000000000233. PMC 4461388. PMID 25714598.
  7. ^ Schmitt C, Mudie N, Ciorciaro C, Gaudreault J (April 2015). "Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers". J. Cardiovasc. Pharmacol. 65 (4): 386–92. doi:10.1097/FJC.0000000000000211. PMID 25602360. S2CID 19526048.
  8. ^ Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L'Allier PL (May 2013). "Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial". J. Am. Coll. Cardiol. 61 (20): 2048–55. doi:10.1016/j.jacc.2013.03.003. PMID 23500230.
  9. ^ Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C (May 2013). "Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies". Thromb. Res. 131 (5): 401–10. doi:10.1016/j.thromres.2013.02.020. PMID 23522853.
  10. ^ "Form 8K - Entry into a Material Definitive Agreement Between Global Blood Therapeutics, Inc. and Hoffmann-La Roche Inc". United States Securities and Exchange Commission.
Categories